|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
In the current study, we used a newly developed enzymatic assay to detect BACE1-NRG1 activity in the human plasma and investigated the levels of cleavage of NRG1 by BACE1 in the plasma from schizophrenia patients.
|
30500411 |
2019 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
BACE1 might be implicated in the pathogenesis of schizophrenia.
|
29500546 |
2018 |
|
Schizophrenia
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Although genetic deletion of BACE1 results in abolished amyloid pathology in AD model mice, it also results in neurodevelopmental phenotypes such as hypomyelination and synaptic loss, observed in schizophrenia and autism-like phenotype.
|
28035928 |
2017 |
|
Schizophrenia
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the association of ERBB4 rs707284 and BACE1 rs490460 with the risk of SZ in an Iranian population.
|
28384043 |
2017 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
Our review will provide a better understanding of Nrg1 in schizophrenia and a potential strategy for using BACE1 cleavage of Nrg1 as a unique biomarker for diagnosis, as well as a new therapeutic target, of schizophrenia.
|
28993723 |
2017 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
PSYGENET |
There was no correlation between the levels of either full-length NRG1, NRG1-CTF, or BACE1 and the final recorded doses of antipsychotic drugs for the subjects with schizophrenia.
|
20926259 |
2010 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
There was no correlation between the levels of either full-length NRG1, NRG1-CTF, or BACE1 and the final recorded doses of antipsychotic drugs for the subjects with schizophrenia.
|
20926259 |
2010 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
PSYGENET |
Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).
|
19536656 |
2009 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
This review summarizes BACE properties, describes BACE translation dysregulation in AD, and discusses BACE physiological functions in sodium current, synaptic transmission, myelination, and schizophrenia.
|
19828790 |
2009 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).
|
19536656 |
2009 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
MGD |
Collectively, our findings suggest that alterations in BACE1-dependent NRG1/ErbB4 signaling may participate in the pathogenesis of schizophrenia and related psychiatric disorders.
|
18385378 |
2008 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
MGD |
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.
|
16354928 |
2005 |